Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anders Pedersen

Showing results (61-70 of 65) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 65 results.
Metabolites|February 21, 2022
Urinary Metabolomic Changes Accompanying Albuminuria Remission following Gastric Bypass Surgery for Type 2 Diabetic Kidney DiseaseWilliam P Martin, Daniel Malmodin, Anders Pedersen, et al.
Clinical Science (London, England : 1979)|October 19, 2022
Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male ratsWilliam P Martin, Meera Nair, Yeong H D Chuah, et al.
Cancer Research|January 25, 2019
An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 BlockadeLynda Vuong, Eleni Kouverianou, Claire M Rooney, et al.
Radiation Oncology (London, England)|August 22, 2022
Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and AsiaBerend J Slotman, Mary Ann Clark, Enis Özyar, et al.
The European Respiratory Journal|November 20, 2020
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosisNikhil Hirani, Alison C MacKinnon, Lisa Nicol, et al.
Pageof 7

Showing results (61-70 of 65) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 65 results.
Metabolites|February 21, 2022
Urinary Metabolomic Changes Accompanying Albuminuria Remission following Gastric Bypass Surgery for Type 2 Diabetic Kidney DiseaseWilliam P Martin, Daniel Malmodin, Anders Pedersen, et al.
Clinical Science (London, England : 1979)|October 19, 2022
Dietary restriction and medical therapy drives PPARα-regulated improvements in early diabetic kidney disease in male ratsWilliam P Martin, Meera Nair, Yeong H D Chuah, et al.
Cancer Research|January 25, 2019
An Orally Active Galectin-3 Antagonist Inhibits Lung Adenocarcinoma Growth and Augments Response to PD-L1 BlockadeLynda Vuong, Eleni Kouverianou, Claire M Rooney, et al.
Radiation Oncology (London, England)|August 22, 2022
Clinical adoption patterns of 0.35 Tesla MR-guided radiation therapy in Europe and AsiaBerend J Slotman, Mary Ann Clark, Enis Özyar, et al.
The European Respiratory Journal|November 20, 2020
Target inhibition of galectin-3 by inhaled TD139 in patients with idiopathic pulmonary fibrosisNikhil Hirani, Alison C MacKinnon, Lisa Nicol, et al.
Pageof 7